Dr. Daniel A. Blaustein, MD

Dr. Blaustein practices at Cooperman Barnabas Medical Center in Livingston, New Jersey, part of RWJBarnabas Health.

Dr. Blaustein's NPI, 1861410540, was assigned on July 18, 2006. Dr. Blaustein holds New Jersey license 25MA08458000.

Dr. Blaustein's primary practice is Cooperman Barnabas Medical Center, at 94 Old Short Hills Road, Livingston, NJ 07039 in Essex County. The practice phone is (973) 322-5000.

Dr. Blaustein's primary practice is Cooperman Barnabas Medical Center in Livingston, New Jersey, part of RWJBarnabas Health. The medical group on file is RWJBarnabas Health Medical Group. Dmand AI also links Dr. Blaustein to 1 more hospice and 1 medical group, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Blaustein practices, 2 sites in all. Vendor and product names are available with a free account.

Nephrology is Dr. Blaustein's primary specialty in the NPI Registry, under taxonomy code 207RN0300X. Dmand AI has Dr. Blaustein's licenses on file in 2 states: New Jersey and New York.

CMS data shows 1,606 Medicare services from Dr. Blaustein across 3 procedure codes in 2024, for 387 Medicare patients. Medicare paid $148,118 for them. Every service was in a facility, such as a hospital, rather than an office.

CMS counts 387 Medicare patients who saw Dr. Blaustein in 2024. The largest group is 75 to 84, with 131 patients. 75% of them have high blood pressure, and 75% have high cholesterol. 22% are also on Medicaid. Their average risk score is 2.63, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Blaustein's median patient age at 76, with 56% women.

In 2024, Dr. Blaustein wrote 490 Medicare Part D claims for 146 patients. 80% of them were for generic drugs. CMS names the drug for 229 of them, across 10 drugs with 11 or more claims each, at $18,693 in total drug cost. In 2023, CMS named 321 claims across 15 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 87 out of 100 for Dr. Blaustein for performance year 2024, reported as part of a group. Dr. Blaustein accepts Medicare assignment, so Medicare's approved amount is taken as full payment.

CMS Open Payments shows 57 general payments to Dr. Blaustein from 14 drug and device companies from 2016 to 2025. Food and beverage make up the largest share, 100% of the total. Bristol-Myers Squibb Company paid the most, $170.